ArticleMediators of inflammation2026
Integrative Multiomics and Network Pharmacology Exploration of Active Components and Mechanisms of Action of Qufu Shengxin Ointment in Treating Chronic Nonhealing Wounds.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic nonhealing wounds (CNHWs) are characterized by persistent inflammation and impaired autophagy, which hinder normal wound repair. Qufu Shengxin Ointment (QFSO) has shown clinical benefits in treating chronic wounds, but its active components and molecular mechanisms remain largely unclear. This study aimed to investigate the pharmacological mechanisms of QFSO in the treatment of CNHWs.
methodsDifferentially expressed genes (DEGs) were identified from Gene Expression Omnibus (GEO) transcriptomic datasets, and weighted gene co-expression network analysis (WGCNA) was performed to screen genes associated with CNHWs. Active compounds and potential targets of QFSO were retrieved from the TCMSP database, and a compound-target network was constructed. Mendelian randomization (MR) analysis was applied to evaluate the potential causal effects of key targets on CNHW risk. Gene set enrichment analysis (GSEA) and immune infiltration analysis were conducted to explore biological functions and immune mechanisms. Molecular docking and in vivo animal experiments were performed to validate the predicted interactions and therapeutic effects.
resultsAbout 1274 DEGs were identified between CNHW and normal wound tissues. Enrichment analyses indicated that the PI3K/Akt/mTOR pathway was significantly involved in CNHW pathogenesis. MR analysis identified AKR1B1 and VCAM1 as potential causal risk factors for CNHWs. Functional enrichment and single-cell RNA sequencing analyses revealed that these genes participate in immune-inflammatory regulation and autophagy-related processes. Molecular docking showed stable binding between key QFSO compounds and the targets AKR1B1 and VCAM1. In vivo experiments demonstrated that QFSO treatment significantly accelerated wound healing. The therapeutic effects were associated with reduced inflammation, enhanced angiogenesis, and activation of autophagy through regulation of the PI3K/Akt/mTOR pathway.
conclusionsQFSO promotes the repair of CNHWs by regulating the PI3K/Akt/mTOR pathway, enhancing autophagy, alleviating inflammation, and promoting angiogenesis. These findings identify AKR1B1 and VCAM1 as potential molecular targets for the treatment of chronic wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.